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Aortic stenosis (AS) due to calcification of the aortic valve is a
common disease, affecting 2–9% of the elderly.1 Due to population
ageing, AS has become a serious healthcare problem for which the
therapeutic options are limited and there are no ‘risk-free’ proce-
dures applicable yet. Progression of AS is substantially unpredictable
and highly variable from patient to patient. In addition, time to
symptom onset, the tipping point from which the prognosis declines,
is also highly variable. Despite feverish efforts to find reliable findings
to predict progression of AS, no universal markers are available to
date. Equally imprecise is our current ability to predict mortality
and the best timing for surgery in asymptomatic AS. Moreover, treat-
ments capable to slowdown or stop the fibrocalcific process taking
place in the valve leaflets are lacking. Such treatments would ultimate-
ly allow prevention of haemodynamic progression and stop transi-
tion from sclerosis to stenosis, reducing morbidity and mortality.
It has been shown that calcific AS and atherosclerosis are closely
related, sharing the same risk factors and common histopathological
processes such as endothelial dysfunction, inflammation, fibrosis, and
calcification. The existence of these common pathways has triggered
studies on lipid-lowering treatments as possible strategies to mitigate
AS evolution. However, all the randomized trials with statins failed to
show any benefit of these drugs in terms of AS progression and out-
comes. These disappointing results confirmed that calcific AS and
atherosclerosis could not be targeted similarly. In atherosclerosis,
lipid accumulation and inflammation play a central role in plaque for-
mation and rupture, whereas in calcific AS, these seem to be early-
phase processes that trigger, precede, and also coexist with bone-like
formation processes.2 Calcification is the leading actor that deter-
mines flow obstruction and poor outcome in AS, while plaque in-
stability is linked to outcome in atherosclerosis. Therefore, statin
therapy that lowers the content of lipids and favours plaque fibrosis
and stabilization is expected to influence positively outcomes in ath-
erosclerosis, but maynot affectoutcome inASwithongoing valve cal-
cification. Positron emission tomography combined with computed
tomography (PET/CT) studies using 18 F fluorodeoxyglucose and
18F-sodium fluoride as tracers have suggested that calcification is
the predominant pathogenic process in AS and may be a more suit-
able target for future therapies aiming to limit AS progression.2 No
randomized studies testing agents that may influence bone formation
pathways are currently available.
The rateofprogression fromasymptomatic to symptomatic, theoc-
currence of adverse events, and the need for aortic valve replacement
are influencednotonlyby the severityof valveobstructionbut alsoby
the degree of left ventricular (LV) structural/functional changes in re-
sponse to chronically increased afterload (i.e. LV remodelling, hyper-
trophy, myocardial fibrosis, decreased longitudinal function).3– 5
Hence, the quest of finding treatment strategies that may positively
influence outcomes in AS may be extended to treatment strategies
designed to preserve myocardial geometry and function.
Inpatientswithheart failureandsystemichypertension, angiotensin-
converting enzyme inhibitors (ACEis) can regress LV hypertrophy and
myocardial fibrosis, irrespective of their blood pressure-lowering
effects, particularly through decreased angiotensin II (ATII) levels.6 In
AS, evolving changes in LV structure are dynamically involved into
the progression from compensatory hypertrophy to LV dysfunction
and heart failure. Myocyte apoptosis and fibrosis play an important
role in this transition. Hence, ACEi, by influencing extracellular
matrix content, including the collagen network, could hypothetically
revert the LV remodelling process. Recently, a decrease in LV end-
systolic volume and brain natriuretic peptide (BNP) was reported in
AS patients randomized to ACEis vs. placebo. An ACEi-mediated LV
unloading effect with a decrease in systemic vascular resistance and
subsequentbenefits to theaortic valve andLV functionweresuggested
as potential mechanistic effects.7 Although this study included a small
numberofpatients (n ¼ 44)andwas limitedbyashort-termfollow-up,
it confirmed and extended previous retrospective data.8 In an animal
mice model, administration of ATII resulted in a significant thickening
of the aortic valve leaflets, suggesting that ATII may also play a direct
role in leaflet fibrosis.9 Moreover, in histological studies on human
stenotic explanted valves, both ATII and ACE were expressed, sup-
porting their role in valve remodelling in humans.10 Interestingly,
chymase, another enzyme that produces ATII, but not influenced by
ACEi, is also expressed in stenotic aortic valves.11 This might partially
explain discordant effects of angiotensin receptor blockers (ARB) and
ACEi on AS progression.10,12,13 In fact, ACEi might not be able to influ-
ence the chymase produced ATII in the aortic valve leaflets.12,13
In this issue of the journal, Bull et al.14 examined, in a randomized
placebo controlled study (RIAS study), the impact of ramipril, an
ACEi, on thedegreeof LVhypertrophy, thechange inLVsystolic func-
tion, the regression of myocardial fibrosis, and the haemodynamic
progression of AS. A total of 100 patients with moderate to severe
AS were randomly assigned to ramipril (2.5–10 mg ad) vs. placebo.
Assessments of myocardial strain (by the tagging technique), the
level of fibrosis (diffuse and replacement), and the myocardial
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perfusion reserve were performed by cardiac magnetic resonance
(CMR) at 6- and 12-month follow-up. Haemodynamic progression
of AS was assessed by both CMR and transthoracic echocardiog-
raphy. Exercise tolerance was evaluated by an exercise treadmill
test. The results showed a progressive (change over the year) signifi-
cant reduction in LV mass (primary end point) as assessed by CMR.
The secondary end points (changes in parameters of LV physiology,
aortic valve area by CMR, BNP levels or exercise tolerance) were
not statistically significant between groups.
First merit of this study is to confirm that ACEis are well tolerated
and can be safely used in AS. Fears to the use of ACEi in patients with
significant AS, theoretical danger of myocardial hypoperfusion and
syncope caused by afterload reduction, have been typically asso-
ciated with underuse of these drugs. ACEi can thus be prescribed
with very few risks in AS.
Second, this studyshowed that ramipril had the potential to reduce
LV mass at 1-year follow-up, irrespective of its blood pressure-
lowering result. This effect was surprisingly independent of any sig-
nificant change in myocardial fibrosis severity. The ramipril group
also showed a trend towards a slower progression of AS, as assessed
by CMR planimetered aortic valve area. Nonetheless, the lack of any
statistically significant difference regarding haemodynamic progres-
sion of AS between groups might be related to the use of an ACEi
with little effects on the aortic valve leaflets metabolic activity, the
methodology used to assess subtle changes in valve stenotic status,
limited follow-up period, or underpowered sample size.
Third, the RIAS study was not designed to evaluate the effects
of ramipril on outcome. It concerned a small number of patients
followed up over 1 year. A larger trial is thus required to determine
whether the observed physiological changes (i.e. LV hypertrophy
regression) are confirmed and might translate into improved
clinical outcomes. In such a larger randomized trial, the evaluation
of new biomarkers of extracellular matrix turnover, the use
of imaging modalities targeting aortic valve metabolic activity
(inflammation, lipid accumulation) (PET/CT), and a direct com-
parison ACEi/ARB might strengthen the added value of medical
treatment in AS. The ongoing ROCK-AS trial (NCT00699452)
using candesartan (ARB) vs. placebo in AS will only partially
address this appeal.
In conclusion, the use of ACEi in AS might modulate the complex
interplay between the LV, the valve, and the systemic vascular system
(Figure 1). However, although the data of the RIAS study are promis-
ing, routine use of ACEis in patients with asymptomatic AS cannot be
systematically recommended at this time.
Conflict of interest: none declared.
References
1. OsnabruggeRL, Mylotte D,HeadSJ, VanMieghemNM, NkomoVT, LeReunCM et al.
Aortic stenosis in the elderly: disease prevalence and numberof candidates for trans-
catheter aortic valve replacement: a meta-analysis and modeling study. J Am Coll
Cardiol 2013;62:1002–12.
2. DweckMR, JonesC, Joshi NV, FletcherAM, RichardsonH,White A et al.Assessment
of valvular calcification and inflammation by positron emission tomography in
patients with aortic stenosis. Circulation 2012;125:76–86.
3. Otto CM, Burwash IG, Legget ME, Munt BI, Fujioka M, Healy NL et al. Prospective
study of asymptomatic valvular aortic stenosis. Clinical, echocardiographic, and ex-
ercise predictors of outcome. Circulation 1997;95:2262–70.
Figure 1 Potential therapeutic strategies to target the valve, the ventricle, or the arterial system in patients with aortic stenosis. Note that ACEis
seem to act at every level of the pathophysiological cascade. ACEi, angiotensin-converting enzyme inhibitors; ARB, angiotensin II receptor blockers;
RANK-inhibitors, receptor activator of nuclear factor K inhibitors.
EditorialPage 2 of 3





4. Cioffi G, Faggiano P, Vizzardi E, Tarantini L, Cramariuc D, Gerdts E et al. Prognostic
effect of inappropriately high left ventricular mass in asymptomatic severe aortic
stenosis. Heart 2011;97:301–7.
5. Herrmann S, StorkS, NiemannM,Lange V, Strotmann JM, Frantz S et al.Low-gradient
aortic valve stenosis myocardial fibrosis and its influence on function and outcome.
J Am Coll Cardiol 2011;58:402–12.
6. Brilla CG, FunckRC, Rupp H. Lisinopril-mediated regressionof myocardial fibrosis in
patients with hypertensive heart disease. Circulation 2000;102:1388–93.
7. Dalsgaard M, Iversen K, Kjaergaard J, Grande P, Goetze JP, Clemmensen P et al.
Short-term hemodynamic effect of angiotensin-converting enzyme inhibition in
patients with severe aortic stenosis: a placebo-controlled, randomized study. Am
Heart J 2014;167:226–34.
8. Nadir MA, Wei L, Elder DH, Libianto R, Lim TK, Pauriah M et al. Impact of
renin-angiotensin system blockade therapy on outcome in aortic stenosis. J Am
Coll Cardiol 2011;58:570–6.
9. Cote N, Pibarot P, Pepin A, Fournier D, Audet A, Arsenault B et al. Oxidized low-
density lipoprotein, angiotensin II and increased waist cirumference are associated
with valve inflammation in prehypertensive patients with aortic stenosis. Int J
Cardiol 2010;145:444–9.
10. O’Brien KD, Shavelle DM, Caulfield MT, McDonald TO, Olin-Lewis K, Otto CM et al.
Association of angiotensin-converting enzyme with low-density lipoprotein in aortic
valvular lesions and in human plasma. Circulation 2002;106:2224–30.
11. Helske S, Lindstedt KA, Laine M, Mayranpaa M, Werkkala K, Lommi J et al. Induction
of local angiotensin II-producing systems in stenotic aortic valves. J Am Coll Cardiol
2004;44:1859–66.
12. Capoulade R, Clavel MA, Mathieu P, Cote N, Dumesnil JG, Arsenault M et al. Impact
of hypertension and renin-angiotensin system inhibitors in aortic stenosis. Eur J Clin
Invest 2013;43:1262–72.
13. Rosenhek R, Rader F, Loho N, Gabriel H, Heger M, Klaar U et al. Statins but not
angiotensin-converting enzyme inhibitors delay progression of aortic stenosis.Circu-
lation 2004;110:1291–5.
14. Bull S, Loudon M, Francis J, Joseph J, Gerry S. A prospective, double-blind, randomised
controlled trial of the angiotensinconvertingenzyme inhibitorRamipril InAortic Sten-
osis (RIAS trial). Eur Heart J Cardiovasc Imaging 2015;doi:10.1093/ehjci/jev043.
Editorial Page 3 of 3
by guest on April 24, 2015
D
ow
nloaded from
 
